Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 32Multiple Endocrine Neoplasia Type 1 9Neoplasms 8Pituitary Neoplasms 7Carcinoid Tumor 7Pituitary ACTH Hypersecretion 6Gastro-enteropancreatic neuroendocrine tumor 6Differentiated Thyroid Cancer 6Adrenocortical Carcinoma 6Thyroid Cancer, Papillary 5Pituitary Diseases 5Pheochromocytoma 5Thyroid Neoplasms 4Serotonin Syndrome 4Neuroblastoma 4Cushing Syndrome 4Breast Neoplasms 4Acromegaly 4ACTH Syndrome, Ectopic 4Sarcoma 3Liposarcoma 3Insulinoma 3Fibrosarcoma 3Endometrial Neoplasms 3Carcinoma, Medullary 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Parkinson Disease 2

Interventions

Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Extrapulmonary Neuroendocrine Cancer × Endocrine × Clear all
NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡